JPRN-jRCT2080222653UnknownPhase 3
Phase III study of AJG511 in patients with active ulcerative colitis
Conditions
Trial Snapshot
- Phase
- Phase 3
- Sponsor
- EA Pharma Co.,Ltd.
- Enrollment
- 120
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 16age old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- •Patients with active ulcerative colitis
Exclusion Criteria
- •Patients with a history of allergic reaction to budesonide
Investigators
Similar Trials
Unknown
Phase 2
Phase II study of AJG511 in patients with active ulcerative colitislcerative colitisJPRN-jRCT2080222245Ajinomoto Pharmaceuticals Co., Ltd.
Completed
Phase 3
Phase III study of AJM300 in patients with active ulcerative colitis (2)Active Ulcerative ColitisJPRN-jRCT2080223867EA Pharma Co., Ltd.198
Unknown
Phase 2
Phase II/III induction study of AJG501 in patients with active ulcerative colitislcerative colitisJPRN-jRCT2080221110Ajinomoto Pharmaceuticals Co., Ltd.
Unknown
Phase 3
Phase 3 study of AJG533 in patients with chronic constipatioChronic constipationJPRN-jRCT2080223008EA Pharma Co.,Ltd.120
Unknown
Phase 3
Phase III Clinical Study of AJG522 : Studies of safety and efficacy of AJG522 as a colon preparation agent for colonoscopy - Comparative study with MGV-5Patients scheduled for colonoscopyJPRN-jRCT2080221438Ajinomoto Pharmaceuticals Co., Ltd.